Skip to content

Efficacy of zinc as an adjunct therapy in the management of severe pneumonia among Gambian children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN33548493
Enrollment
600
Registered
2005-10-21
Start date
2005-10-24
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe and very severe pneumonia defined clinically Respiratory Pneumonia

Interventions

Interventions amended as of 17/09/2007: Zinc sulphate or placebo. Zinc will be given once daily orally at a dose of 10 mg in those aged 2-11 months and 20 mg in those 12-59 months. All participants
zinc sulphate has been used throughout the trial. Interventions provided at time of registration: Zinc acetate or placebo. Zinc will be given once daily orally at a dose of 10 mg in those aged 2-11

Sponsors

Medical Research Council (UK)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Prior to 18/10/10: Children aged 2-59 months presenting with severe or very severe pneumonia to the MRC Hospital or the Royal Victoria Teaching Hospital, Banjul. Modified on 18/10/10: 'Children aged 2-59 months presenting with severe or very severe pneumonia to the MRC Hospital, the Royal Victoria Teaching Hospital, Banjul, and the health centres at Fajikunda, Brikama, Serekunda and Basse.

Exclusion criteria

Exclusion criteria: Children with severe malnutrition or signs of systemic infection other than pneumonia

Design outcomes

Primary

MeasureTime frame
Treatment failure at 5 days

Secondary

MeasureTime frame
The following will be assessed after 6 months supplementation of zinc or placebo in a subgroup: 1. Time to resolution of signs of severe and very severe pneumonia 2. Length of admission 3. Height 4. Multi-antigen skin testing

Countries

Gambia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 24, 2026